| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ITGA2; BR; GPIa; HPA-5; VLA-2; VLAA2 |
| Entrez GeneID | 3673 |
| clone | 5E3A8 |
| WB Predicted band size | 129.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD49B (AA: extra 994-1132) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MyD88抗体的3篇参考文献示例(内容基于公开研究整理，非真实文献)：
1. **文献名称**: *MyD88-dependent signaling drives Toll-like receptor-induced cytokine production in macrophages*
**作者**: Kawai T, Akira S
**摘要**: 研究通过Western blot和免疫沉淀技术，利用MyD88特异性抗体证明MyD88在TLR4激活后NF-κB通路中的关键作用，抗体用于验证基因敲除模型的蛋白缺失。
2. **文献名称**: *Somatic mutations in MYD88 define a subset of lymphoid malignancies*
**作者**: Ngo VN, Young RM, et al.
**摘要**: 该研究使用抗MyD88抗体(克隆号：D80F5)通过免疫组化和测序技术，在弥漫大B细胞淋巴瘤患者中发现MyD88 L265P突变，揭示其与异常炎症信号通路的关联。
3. **文献名称**: *Evaluation of MyD88 antibody specificity in murine inflammatory disease models*
**作者**: Loiarro M, et al.
**摘要**: 对比多种商业化MyD88抗体的特异性，通过流式细胞术和免疫荧光验证其在野生型与MyD88敲除小鼠中的检测效果，为炎症性疾病研究提供抗体选择依据。
MyD88 (Myeloid Differentiation Primary Response 88) is a critical adaptor protein in innate immune signaling, primarily involved in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways. It mediates downstream signaling by recruiting kinases like IRAKs, leading to NF-κB activation and pro-inflammatory cytokine production. MyD88 antibodies are essential tools for studying immune responses, inflammation, and related diseases. Researchers use these antibodies to detect MyD88 expression, localization, and activation in various cells and tissues through techniques like Western blot, immunohistochemistry, and flow cytometry.
MyD88 dysregulation is linked to cancers (e.g., lymphomas), autoimmune disorders, and chronic infections. Notably, somatic MyD88 mutations (e.g., L265P) are biomarkers in lymphoproliferative diseases, making MyD88 antibodies vital for diagnostic assays. Additionally, they aid in exploring therapeutic strategies targeting MyD88-dependent pathways, such as TLR inhibitor development. Available as monoclonal or polyclonal forms, these antibodies vary in specificity across species (human, mouse, rat), requiring validation for experimental accuracy. Overall, MyD88 antibodies bridge basic research and clinical applications, enhancing understanding of immune pathogenesis and therapeutic innovation.
×
